ArticleBMC psychiatry2026
Comparative cross-sectional analysis of the Griffiths III and the Developmental Autism Early Screening (DAES) test in children with neurodevelopmental disorders.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobal Developmental Delay (DD) and Autism Spectrum Disorder (ASD), are neurodevelopmental disorders (NDDs) characterized by early impairments in communication, cognition, and socio-emotional functioning. Early identification remains challenging due to symptom heterogeneity and overlaps across conditions. We aimed to investigate possible differences in the early developmental profiles among children aged 18 to 48 months at risk for NDDs using the Griffiths Mental Development Scales (Griffiths III) and the Developmental Autism Early Screening (DAES), an observational and interactive Level 2 screening tool.
methodsSignificant differences across the developmental domains assessed with the Griffiths III and the DAES were examined by comparing children referred for risk of ASD or DD with a control group of typically developing children (CTRL). A total of 310 participants were enrolled. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the DAES total score were calculated. Spearman's rank correlation was used to assess the association between the DAES total score and the ADOS-2 Calibrated Severity Score (CSS).
resultsSignificant differences emerged between groups across the Griffiths III subscales, with the most pronounced impairments observed in the Language and Communication (p < 0.00001) and Personal-Social-Emotional (p < 0.00001) domains. DAES total scores significantly differentiated the groups, with the highest scores recorded in the ASD cohort with respect to DD (p = 0.0004) and CTRL (p = 0.00001). Notably, higher DAES scores were associated with greater ASD symptom severity as measured by the ADOS-2 CSS (p = 0.013).
conclusionThe study highlights the clinical value of using Griffiths III and the DAES to support the early identification of children at risk for ASD compared with those with developmental delay (DD) and typical development. Integrating these measures into routine clinical assessment may improve the early detection of atypical developmental trajectories and guide individualized intervention planning during critical periods of neurodevelopment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.